Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9 (Q28290776)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

M Muszkat

series ordinal

1

0 references

language of work or name

English

0 references

publication date

28 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

215-218

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

Systematic review: antihypertensive drug therapy in black patients

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Pharmacology and physiology of human adrenergic receptor polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Molecular basis of ethnic differences in drug disposition and response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Whole-genome patterns of common DNA variation in three human populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Population genetic structure of variable drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Conceptualizing human variation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Ethnic differences in drug disposition and responsiveness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Clinical consequences of cytochrome P450 2C9 polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100142

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100142

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17329986%20AND%20SRC:MED&resulttype=core&format=json

release_kmddjbwqnne5nnu4jhzdurwet4

26 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kmddjbwqnne5nnu4jhzdurwet4

24 November 2022

mapped directly with Wikidata item

1 reference